CurrentEndo
Get Weekly

CurrentEndo coverage · page 15 of 55

Diabetes, Obesity and Metabolism

Briefs 561–600 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    The 1‐Hour Plasma Glucose for Early Risk Stratification in Young, Obese Chinese Adults: Implications for Clinical Management

    Cross-sectional studyObesity

  2. Diabetes Obes Metab

    Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN ‐ II and RED ‐ CARPET Cohorts

    Cohort studyComplications

  3. Diabetes Obes Metab

    Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting

    Meta-analysisT2D & other

  4. Diabetes Obes Metab

    Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study

    Research articleT2D & other

  5. Diabetes Obes Metab

    Identification of Common Blood Metabolic Derangements Using Magnetic Resonance Signatures of the Pancreas and Liver

    Cross-sectional studyLipids & liver

  6. Diabetes Obes Metab

    Impact of early and tight HbA1c control on the risk of long‐term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register

    Cohort studyT2D & other

  7. Diabetes Obes Metab

    Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study

    Cohort study

  8. Diabetes Obes Metab

    Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

    Cohort studyT2D & other

  9. Diabetes Obes Metab

    Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

    Cohort study

  10. Diabetes Obes Metab

    Visit‐to‐visit HbA1c variability, risk of all‐cause mortality and diabetes‐related vascular complications among adult individuals with type 2 diabetes mellitus

    Cohort studyComplications

  11. Diabetes Obes Metab

    Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

    Cohort studyT2D & other

  12. Diabetes Obes Metab

    Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

    Cohort studyT2D & other

  13. Diabetes Obes Metab

    Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study

    Cross-sectional studyObesity

  14. Diabetes Obes Metab

    Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials

    Meta-analysisT2D & other

  15. Diabetes Obes Metab

    Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX ‐ SEMA 2.4 mg, an Italian real‐world study

    Cohort studyObesity

  16. Diabetes Obes Metab

    Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12‐month observational cohort study

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    Real‐world predictors of progression to type 2 diabetes among adults with prediabetes

    Case-control studyT2D & other

  18. Diabetes Obes Metab

    Sex‐specific associations of body mass index and waist circumference loss with the risk of atrial fibrillation

    Cohort studyObesity

  19. Diabetes Obes Metab

    Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Associations of obesity, systemic inflammation, and hyperinsulinemia with the incidence of non‐communicable chronic disease and mortality: A prospective cohort study

    Cohort studyObesity

  21. Diabetes Obes Metab

    Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    Performance of an automated insulin‐glucagon delivery system versus automated insulin delivery system during challenging inpatient conditions. A single‐blind randomised controlled crossover trial

    Randomized controlled trialTechnology

  23. Diabetes Obes Metab

    A retrospective observational study evaluating the safety and effectiveness of commercially available automated insulin delivery systems in people with type 1 diabetes and gastroparesis

    Cohort studyTechnology

  24. Diabetes Obes Metab

    Uptake and early outcomes of a meal replacement intervention in an ethnically diverse adult population living with obesity and significant comorbidity

    Cohort studyObesity

  25. Diabetes Obes Metab

    Associations between use of aspirin and magnetic resonance imaging‐derived liver fat and fibroinflammation

    Cohort studyLipids & liver

  26. Diabetes Obes Metab

    Associations of metformin and sulfonylurea on vascular complications in early‐ and late‐onset type 2 diabetes: A cohort study

    Cohort studyT2D & other

  27. Diabetes Obes Metab

    Baseline and 4‐year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort

    Cross-sectional studyT2D & other

  28. Diabetes Obes Metab

    Causal role of genetically predicted impairment of branched‐chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes

    Meta-analysisT2D & other

  29. Diabetes Obes Metab

    Association between the oxidative balance score and risk of microvascular complications in type 2 diabetes: A prospective UK biobank cohort study

    Cohort studyComplications

  30. Diabetes Obes Metab

    Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system

    Cohort studyObesity

  31. Diabetes Obes Metab

    Pathways between race, structural racism, and obesity across census tracts in the United States

    Cross-sectional studyObesity

  32. Diabetes Obes Metab

    Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China

    Research articleT2D & other

  33. Diabetes Obes Metab

    Unveiling glycaemic variability patterns linked to the triglyceride‐glucose index in type 2 diabetes: Insights from continuous glucose monitoring

    Cross-sectional studyTechnology

  34. Diabetes Obes Metab

    Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans

    Cross-sectional studyT2D & other

  35. Diabetes Obes Metab

    Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta‐analysis

    Meta-analysisObesity

  36. Diabetes Obes Metab

    Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial

    Randomized controlled trialT2D & other

  37. Diabetes Obes Metab

    Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

    Cohort studyT2D & other

  38. Diabetes Obes Metab

    Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

    Cohort studyT2D & other

  39. Diabetes Obes Metab

    Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)

    Trial designObesity

  40. Diabetes Obes Metab

    Sex‐specific changes in GLP ‐ 1RA trends (2019–2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States

    Research articleObesity

All 2,200 Briefs in ExploreShowing Briefs 561–600 of 2,200, newest first